Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH-Reference-Cited by-同舟云学术

Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Published:2018-02-05 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Shiba Kumiko,Tsuchiya Kyoichiro,Komiya Chikara,Miyachi Yasutaka,Mori Kentaro,Shimazu Noriko,Yamaguchi Shinobu^ORCID,Ogasawara Naomi,Katoh Makoto,Itoh Michiko,Suganami Takayoshi,Ogawa Yoshihiro

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-19658-7.pdf

Reference55 articles.

1. Rinella, M. E. Nonalcoholic fatty liver disease: a systematic review. JAMA 313, 2263–2273, https://doi.org/10.1001/jama.2015.5370 (2015).

2. Brunt, E. M. et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1, 15080, https://doi.org/10.1038/nrdp.2015.80 (2015).

3. Neuschwander-Tetri, B. A. & Caldwell, S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202–1219, https://doi.org/10.1053/jhep.2003.50193 (2003).

4. Dunn, W. & Schwimmer, J. B. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 10, 67–72 (2008).

5. Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419 (1999).

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders;Pharmacology & Therapeutics;2024-10

2. The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-09-10

3. Pharmacological targets of SGLT2 inhibition on prostate cancer mediated by circulating metabolites: a drug-target Mendelian randomization study;Frontiers in Pharmacology;2024-08-06

4. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors;JACC: CardioOncology;2024-04

5. Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential;Frontiers in Pharmacology;2024-03-26